Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | ROS1 | P08922 | 6/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126649 | 0.92 | PTK2 (0.49) | PTK2EGFRLRRK2ROS1ALK | |
| SCHEMBL2874807 | 0.90 | EGFR (0.48) | PTK2EGFRLRRK2ROS1ALK | |
| SCHEMBL2122465 | 0.89 | EGFR (0.51) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL2126176 | 0.88 | EGFR (0.46) | PTK2EGFRLRRK2ROS1ALK | |
| SCHEMBL2125435 | 0.87 | EGFR (0.49) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL2124409 | 0.86 | EGFR (0.47) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL2127634 | 0.85 | EGFR (0.48) | EGFRLRRK2ROS1ALKMET | |
| SCHEMBL2128831 | 0.84 | EGFR (0.52) | PTK2EGFRLRRK2ROS1ALK | |
| SCHEMBL2141553 | 0.84 | EGFR (0.48) | EGFRLRRK2ROS1ALK | |
| SCHEMBL2121158 | 0.84 | EGFR (0.50) | EGFRLRRK2ROS1ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2443106-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2443106-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | Cellzome Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010146133-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172384-A1 | HETEROCYCLYLAMINOPYRIMIDINES AS KINASE INHIBITORS | ZAP70, JAK3, JAK2 | PTK2 168/4885EGFR 785/4885LRRK2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.